Gland Pharma, a pharmaceutical company, has obtained an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Visakhapatnam facility. The USFDA closed the inspection of Gland Pharma’s Vizag unit, which took place from July 20 to July 28.
The inspection was related to ‘Good Manufacturing Practice (GMP) Inspection. Despite a 20% year-on-year decline in net profit to Rs 194 crore, Gland Pharma reported a significant 32% increase in revenue from operations, amounting to Rs 1,373 crore. This growth was driven by higher sales resulting from the acquisition of the French pharmaceutical group Cenexi.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
